106 related articles for article (PubMed ID: 23334134)
1. Unusual case of isolated parasellar metastasis from carcinoma of thyroid.
Malhotra G; Asopa RV; Sridhar E
Clin Nucl Med; 2013 Feb; 38(2):145-8. PubMed ID: 23334134
[TBL] [Abstract][Full Text] [Related]
2. Effect of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography-guided management of suspected recurrent papillary thyroid carcinoma: long-term follow-up with tumour marker responses.
Dennis K; Hay JH; Wilson DC
Clin Oncol (R Coll Radiol); 2012 Dec; 24(10):e168-72. PubMed ID: 22944464
[TBL] [Abstract][Full Text] [Related]
3. Unusual case of adrenal and renal metastases from papillary carcinoma of thyroid.
Malhotra G; Upadhye TS; Sridhar E; Asopa RV; Garde PS; Gawde S; Rangarajan V
Clin Nucl Med; 2010 Sep; 35(9):731-6. PubMed ID: 20706057
[TBL] [Abstract][Full Text] [Related]
4. The role of 18F-Fluorodeoxyglucose Positron Emission Tomography in patients with suspected recurrence or metastatic differentiated thyroid carcinoma with elevated serum thyroglobulin and negative I-131 whole body scan.
Trybek T; Kowalska A; Lesiak J; Młynarczyk J
Nucl Med Rev Cent East Eur; 2014; 17(2):87-93. PubMed ID: 25088108
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
[TBL] [Abstract][Full Text] [Related]
6. Detection of intraluminal tracheal metastasis of thyroid papillary carcinoma by 18F-FDG PET/CT.
Ozkan E; Araz M; Soydal C; Kucuk NO; Ibis E
Clin Nucl Med; 2012 Jun; 37(6):e160-1. PubMed ID: 22614217
[TBL] [Abstract][Full Text] [Related]
7. 18F-FDG PET/CT demonstration of a liver metastasis in a patient with papillary thyroid cancer.
Mosci C; McDougall IR; Jeffrey RB; Iagaru A
Clin Nucl Med; 2012 Sep; 37(9):e234-6. PubMed ID: 22889801
[TBL] [Abstract][Full Text] [Related]
8. Role of [(18)F]-fluorodeoxy-D-glucose positron emission tomography and computed tomography in the early detection of persistent/recurrent thyroid carcinoma in intermediate-to-high risk patients following initial radioactive iodine ablation therapy.
Kim MH; O JH; Ko SH; Bae JS; Lim DJ; Kim SH; Baek KH; Lee JM; Kang MI; Cha BY; Lee KW
Thyroid; 2012 Feb; 22(2):157-64. PubMed ID: 22224820
[TBL] [Abstract][Full Text] [Related]
9. Impact of FDG-PET computed tomography for surgery of recurrent or persistent differentiated thyroid carcinoma.
Weber T; Ohlhauser D; Hillenbrand A; Henne-Bruns D; Reske SN; Luster M
Horm Metab Res; 2012 Nov; 44(12):904-8. PubMed ID: 22791600
[TBL] [Abstract][Full Text] [Related]
10. Respective roles of thyroglobulin, radioiodine imaging, and positron emission tomography in the assessment of thyroid cancer.
Lind P; Kohlfürst S
Semin Nucl Med; 2006 Jul; 36(3):194-205. PubMed ID: 16762610
[TBL] [Abstract][Full Text] [Related]
11. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
12. Combined [18F]Fluorodeoxyglucose positron emission tomography and computed tomography (FDG-PET/CT) for detection of recurrent, 131I-negative thyroid cancer.
Finkelstein SE; Grigsby PW; Siegel BA; Dehdashti F; Moley JF; Hall BL
Ann Surg Oncol; 2008 Jan; 15(1):286-92. PubMed ID: 17882493
[TBL] [Abstract][Full Text] [Related]
13. Asymptomatic solitary cerebral metastasis from papillary carcinoma thyroid: 131I SPECT/CT for accurate staging.
Jain TK; Karunanithi S; Sharma P; Vijay MK; Ballal S; Bal C
Clin Nucl Med; 2014 Nov; 39(11):977-9. PubMed ID: 24566406
[TBL] [Abstract][Full Text] [Related]
14. Diffuse pulmonary metastases with negative ¹⁸FDG positron emission tomography/computed tomography and positive post-radioiodine therapy scan of papillary thyroid cancer.
Lin YS; Liang ZY; Qiu LH; Cheng X
Chin Med J (Engl); 2012 Jan; 125(1):153-6. PubMed ID: 22340484
[TBL] [Abstract][Full Text] [Related]
15. Clinical utility of 18F-FDG PET/CT concurrent with 131I therapy in intermediate-to-high-risk patients with differentiated thyroid cancer: dual-center experience with 286 patients.
Lee JW; Lee SM; Lee DH; Kim YJ
J Nucl Med; 2013 Aug; 54(8):1230-6. PubMed ID: 23813775
[TBL] [Abstract][Full Text] [Related]
16. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
[TBL] [Abstract][Full Text] [Related]
17. F-18 FDG PET/CT demonstration of an adrenal metastasis in a patient with anaplastic thyroid cancer.
Iagaru A; McDougall IR
Clin Nucl Med; 2007 Jan; 32(1):13-5. PubMed ID: 17179796
[TBL] [Abstract][Full Text] [Related]
18. The added clinical value of 18F-FDG PET/CT in evaluating intratracheal recurrence of differentiated thyroid carcinoma: implications for planning surgery, assessing its completeness, and planning radioiodine therapy.
Basu S; Abhyankar A
J Nucl Med Technol; 2013 Dec; 41(4):302-5. PubMed ID: 24159010
[TBL] [Abstract][Full Text] [Related]
19. Is it practical and cost effective to detect differentiated thyroid carcinoma metastases by (18)F-FDG PET/CT, by (18)F-FDG SPET/CT or by (131)I SPET/CT?
He X; Wang X; Yu J; Ma C
Hell J Nucl Med; 2015; 18(1):2-4. PubMed ID: 25679071
[TBL] [Abstract][Full Text] [Related]
20. [Thymic uptake of 18FFDG following radioiodine ablation therapy].
Albalá González MD; Martínez Gimeno E; Cárdenas Negro C; Allende Riera A; Cabello García D; De Sequera Rahola M; Uña Gorospe JA
Rev Esp Med Nucl; 2011; 30(5):314-6. PubMed ID: 21342725
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
